# Wegovy Reduces Migraine Severity, Particularly for Women
Semaglutide, the active ingredient in Wegovy, appears to ease migraine intensity beyond its primary weight-loss effect. A new analysis shows the medication reduces migraine severity in patients who take it, with women experiencing the most dramatic improvements.
The finding emerges from research examining how GLP-1 receptor agonists like semaglutide affect neurological symptoms. Researchers discovered that patients using Wegovy reported fewer severe migraine episodes and reduced frequency of attacks. Women saw greater relief than men in the studies reviewed.
This benefit likely stems from multiple mechanisms. Weight loss itself can reduce migraine triggers in some patients. Semaglutide also stabilizes blood sugar levels, reducing metabolic fluctuations that can spark migraines. The medication's anti-inflammatory properties may protect nerve pathways involved in migraine development.
For families managing chronic migraines, this finding adds another layer to conversations about Wegovy. Parents of teenagers or adults struggling with both weight and frequent migraines should discuss this potential benefit with their doctors. The medication typically costs between $900 and $1,350 monthly, though insurance coverage varies.
Neurologists and headache specialists note that Wegovy works best alongside other migraine strategies. Lifestyle changes, stress management, and adequate sleep remain foundational. Some patients still need traditional migraine medications alongside semaglutide.
The gender difference warrants attention. Migraines affect women three times more often than men, and hormonal factors play a significant role. The enhanced benefit in women suggests semaglutide may interact favorably with migraine biology in ways researchers are still exploring.
Before starting Wegovy, families should understand it carries side effects like nausea and gastrointestinal changes. These typically decrease over time as bodies